BlackRock Institutional Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Institutional Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$73.2M	Buy	1,953,854 +51,511	+3%	+$2.16M	0.01%	1111
2016 Q3	$129M	Sell	1,902,343 -23,987	-1%	-$1.69M	0.02%	748
2016 Q2	$107M	Buy	1,926,330 +149,671	+8%	+$9.43M	0.02%	814
2016 Q1	$112M	Buy	1,776,659 +3,770	+0.2%	+$251K	0.02%	781
2015 Q4	$167M	Buy	1,772,889 +11,275	+0.6%	+$1.05M	0.03%	616
2015 Q3	$142M	Buy	1,761,614 +9,049	+0.5%	+$1.01M	0.02%	663
2015 Q2	$210M	Sell	1,752,565 -6,769	-0.4%	-$809K	0.03%	539
2015 Q1	$184M	Buy	1,759,334 +156,051	+10%	+$15.8M	0.03%	610
2014 Q4	$156M	Buy	1,603,283 +9,813	+0.6%	+$909K	0.02%	652
2014 Q3	$124M	Buy	1,593,470 +35,771	+2%	+$2.31M	0.02%	725
2014 Q2	$98.4M	Buy	1,557,699 +37,106	+2%	+$2.21M	0.02%	905
2014 Q1	$102M	Buy	1,520,593 +31,555	+2%	+$2.44M	0.02%	863
2013 Q4	$95.7M	Buy	1,489,038 +809	+0.1%	+$48.3K	0.02%	877
2013 Q3	$95.3M	Buy	1,488,229 +14,911	+1%	+$743K	0.02%	818
2013 Q2	$45.7M	Buy	+1,473,318	New	+$39.2M	0.01%	1214

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BlackRock Institutional Trust's ALNY Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 2.7% in Q4 2016, buying an estimated $2.16M and bringing the position to 1,953,854 shares worth $73.2M. The position accounts for 0.01% of the portfolio, ranked #1111.

BlackRock Institutional Trust first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $210M in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

BlackRock Institutional Trust held 1,953,854 shares of Alnylam Pharmaceuticals worth $73.2M as of Q4 2016.
BlackRock Institutional Trust bought 51,511 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $2.16M.
Alnylam Pharmaceuticals made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1111 holding.
BlackRock Institutional Trust first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Alnylam Pharmaceuticals position peaked at $210M in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.